Brolucizumab-Dbll vs Surabgene lomparvovec
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Brolucizumab-Dbll
Marketed by Novartis and partners
NCT05672979 · Phase 3 · status unknown
This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.
No aligned efficacy figure on record for this race.
Surabgene lomparvovec
Developed by AbbVie and partners
NCT04832724 · Phase 2 · completed
The study enrolled 60 participants into sequential RGX-314 dose and formulation groups without randomization, blinding, or a comparator arm. Its primary endpoint was the surrogate pharmacodynamic measure of RGX-314 protein concentration, and no primary outcome results are available.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
Reported efficacy
RGX-314 target protein concentration in aqueous humor (At Week 24): Primary endpoint (aqueous RGX-314 protein at Month 6, high-dose cohorts): 511.7 ng/mL (BRX process, n=14) vs 436.3 ng/mL (HS process, n=14); 80% CI of the difference (-38, 189) overlaps 0 (not_applicable)
Result source: NCT04832724
Results for Age-Related Macular Degeneration
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Brolucizumab-Dbll: registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Surabgene lomparvovec
show 4 more results
show 4 more results
show 4 more results
show 4 more results
Available safety results
Surabgene lomparvovec
| Dropout rate | 16.7%Cohort 1 NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results0%Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence 0%Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence 0%Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence 8.3%Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | —Cohort 1 NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results—Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence —Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 33.3%Cohort 1 NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more results33.3%Cohort 2 NCT03066258 · Phase 1/2 · registry result, not featured evidence 16.7%Cohort 3 NCT03066258 · Phase 1/2 · registry result, not featured evidence 25%Cohort 4 NCT03066258 · Phase 1/2 · registry result, not featured evidence 33.3%Cohort 5 NCT03066258 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | intraocular inflammation 66.7% retinal haemorrhage 66.7% visual acuity reduced/impairment 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence show 4 more resultsconjunctival haemorrhage 50% intraocular inflammation 50% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence conjunctival haemorrhage 66.7% intraocular inflammation 50% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 50% NCT03066258 · Phase 1/2 · registry result, not featured evidence retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 100% conjunctival haemorrhage 75% retinal thickening 33.3% NCT03066258 · Phase 1/2 · registry result, not featured evidence conjunctival haemorrhage 91.7% retinal pigmentary changes (depigmentation, pigment epitheliopathy & pigmentation) 91.7% eye irritation 33.3% NCT03066258 · Phase 1/2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brolucizumab-Dbll's landscape · Surabgene lomparvovec's landscape